Solid biosciences to participate at the jefferies gene therapy/editing summit

Cambridge, mass., oct. 21, 2021 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company focused on advancing meaningful therapies for duchenne muscular dystrophy (duchenne), today announced that ilan ganot, co-founder, president and chief executive officer, and carl morris, phd, chief scientific officer, will participate in a fireside chat at the jefferies gene therapy/editing summit on thursday, october 28, 2021 at 2:00 p.m. et.
SLDB Ratings Summary
SLDB Quant Ranking